Novartis Offers Free Genetic Mutation Testing for Some Melanoma Patients
July 11 2019 - 2:22PM
Dow Jones News
By Stephen Nakrosis
Novartis AG (NVS) said Thursday it is offering free genetic
testing to patients with Stage III and Stage IV melanoma, to
determine if the patients have a genetic mutation which could
impact their treatment options.
The "Know Now Testing Program" will enable patients to determine
if they carry a specific mutation, called BRAF.
"At Novartis, we know that understanding potential mutations is
critical for melanoma patients and their doctors to make informed
treatment decisions," said Ameet Mallik, Executive Vice President
and Head, U.S., Novartis Oncology.
Test results will be available about 48 hours after a Quest
Diagnostics laboratory receives a sample, Novartis said.
--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
July 11, 2019 14:07 ET (18:07 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novartis (NYSE:NVS)
Historical Stock Chart
From Apr 2023 to Apr 2024
